TAK 165 | 1951

Cell-permeable. A potent inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase (IC₅₀ = 6 nM). Displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. TAK 165 inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

TAK-165 is a potent inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase (IC₅₀ = 6 nM). Displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. TAK 165 inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

1951 | TAK 165 DataSheet

Alternate Name/Synonyms: (E)-4-((4-)1H-1,2,3-Triazol-1-yl)butyl)phenoxy)methyl)-2-(4-trifluoromethyl)oxazole; Mubritinib

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 366017-09-6

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₅H₂₃F₃N₄O₂

Molecular Weight: 468.47

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~25 mg/ml) or EtOH (~ 1.7 mg/ml)

Handling: Protect from light and air

Country of Origin: USA

Tag Line: A potent HER2 tyrosine kinase inhibitor

MDL Number: MFCD09954135

PubChem CID: 6444692

SMILES: C1=CC(=CC=C1CCCCN2C=CN=N2)OCC3=COC(=N3)C=CC4=CC=C(C=C4)C(F)(F)F

InChi: InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+

InChi Key: ZTFBIUXIQYRUNT-MDWZMJQESA-N